Evidence map›Paper›PMID 27508007›Full record

ArticleHereditary cancer in clinical practice2016

Pedigree based DNA sequencing pipeline for germline genomes of cancer families.

Asta Försti, Abhishek Kumar, Nagarajan Paramasivam, Matthias Schlesner, Calogerina Catalano, Dagmara Dymerska, Jan Lubinski, Roland Eils, Kari Hemminki

Abstract read
In one paragraph

Article in Hereditary cancer in clinical practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Asta Försti *Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), D69120 Heidelberg, Germany.
Abhishek Kumar *Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), D69120 Heidelberg, Germany.
Nagarajan Paramasivam *Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), D69120 Heidelberg, Germany.
Matthias Schlesner *Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), D69120 Heidelberg, Germany.
Calogerina CatalanoDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), D69120 Heidelberg, Germany.
Dagmara DymerskaHereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Jan LubinskiHereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Roland EilsDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), D69120 Heidelberg, Germany.
Kari HemminkiDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), D69120 Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the course of our whole-genome sequencing efforts, we have developed a pipeline for analyzing germline genomes from Mendelian types of cancer pedigrees (familial cancer variant prioritization pipeline, FCVPP).

resultsThe variant calling step distinguishes two types of genomic variants: single nucleotide variants (SNVs) and indels, which undergo technical quality control. Mendelian types of variants are assumed to be rare and variants with frequencies higher that 0.1 % are screened out using human 1000 Genomes (Phase 3) and non-TCGA ExAC population data. Segregation in the pedigree allows variants to be present in affected family members and not in old, unaffected ones. The effectiveness of variant segregation depends on the number and relatedness of the family members: if over 5 third-degree (or more distant) relatives are available, the experience has shown that the number of likely variants is reduced from many hundreds to a few tens. These are then subjected to bioinformatics analysis, starting with the combined annotation dependent depletion (CADD) tool, which predicts the likelihood of the variant being deleterious. Different sets of individual tools are used for further evaluation of the deleteriousness of coding variants, 5' and 3' untranslated regions (UTRs), and intergenic variants. CONLUSIONS: The likelihood of success of the present genomic pipeline in finding novel high- or medium-penetrant genes depends on many steps but first and foremost, the pedigree needs to be reasonably large and the assignments and diagnoses among the members need to be correct.

Indexed as

Family-basedGenetic risk factorsGermline geneticsMutation

Identifiers

PMID27508007
PMCPMC4977614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.